| Year |
Citation |
Score |
| 2023 |
Neely V, Manchikalapudi A, Nguyen K, Dalton K, Hu B, Koblinski JE, Faber AC, Deb S, Harada H. Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment. International Journal of Molecular Sciences. 24. PMID 37685889 DOI: 10.3390/ijms241713082 |
0.619 |
|
| 2021 |
Vaughan CA, Singh S, Subler MA, Windle JJ, Inoue K, Fry EA, Pillappa R, Grossman SR, Windle B, Andrew Yeudall W, Deb SP, Deb S. The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3. Nature Communications. 12: 704. PMID 33514736 DOI: 10.1038/s41467-021-20928-8 |
0.6 |
|
| 2019 |
Singh S, Vaughan CA, Rabender C, Mikkelsen R, Deb S, Palit Deb S. DNA replication in progenitor cells and epithelial regeneration after lung injury requires the oncoprotein MDM2. Jci Insight. PMID 31527309 DOI: 10.1172/Jci.Insight.128194 |
0.4 |
|
| 2017 |
Vaughan CA, Singh S, Grossman SR, Windle B, P Deb S, Deb S. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells. Molecular Oncology. PMID 28423230 DOI: 10.1002/1878-0261.12068 |
0.628 |
|
| 2017 |
Singh S, Vaughan CA, Frum RA, Grossman SR, Deb S, Deb SP. Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication. The Journal of Clinical Investigation. PMID 28394262 DOI: 10.1172/Jci87724 |
0.681 |
|
| 2016 |
Frum RA, Love IM, Damle P, Mukhopadhyay ND, Palit Deb S, Deb S, Grossman SR. Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination. Molecular Cancer Research : McR. PMID 26965143 DOI: 10.1158/1541-7786.Mcr-15-0363 |
0.668 |
|
| 2016 |
Vaughan CA, Pearsall I, Singh S, Windle B, Deb SP, Grossman SR, Yeudall WA, Deb S. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter. Oncotarget. PMID 26820293 DOI: 10.18632/Oncotarget.6998 |
0.589 |
|
| 2014 |
Gadepalli VS, Deb SP, Deb S, Rao RR. Lung cancer stem cells, p53 mutations and MDM2. Sub-Cellular Biochemistry. 85: 359-70. PMID 25201204 DOI: 10.1007/978-94-017-9211-0_19 |
0.474 |
|
| 2014 |
Deb SP, Singh S, Deb S. MDM2 overexpression, activation of signaling networks, and cell proliferation. Sub-Cellular Biochemistry. 85: 215-34. PMID 25201197 DOI: 10.1007/978-94-017-9211-0_12 |
0.389 |
|
| 2014 |
Vaughan C, Pearsall I, Yeudall A, Deb SP, Deb S. p53: its mutations and their impact on transcription. Sub-Cellular Biochemistry. 85: 71-90. PMID 25201189 DOI: 10.1007/978-94-017-9211-0_4 |
0.673 |
|
| 2014 |
Vaughan CA, Deb SP, Deb S, Windle B. Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites. Oncotarget. 5: 417-27. PMID 24481480 DOI: 10.18632/Oncotarget.1708 |
0.466 |
|
| 2014 |
Frum RA, Singh S, Vaughan C, Mukhopadhyay ND, Grossman SR, Windle B, Deb S, Deb SP. The human oncoprotein MDM2 induces replication stress eliciting early intra-S-phase checkpoint response and inhibition of DNA replication origin firing. Nucleic Acids Research. 42: 926-40. PMID 24163099 DOI: 10.1093/Nar/Gkt944 |
0.469 |
|
| 2013 |
Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, Tokarz M, Adams BR, Wagner AF, Khalil A, Gilfor D, Golding SE, Deb S, Temesi DG, Lau A, O'Connor MJ, et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3189-200. PMID 23620409 DOI: 10.1158/1078-0432.Ccr-12-3408 |
0.499 |
|
| 2013 |
Singh S, Ramamoorthy M, Vaughan C, Yeudall WA, Deb S, Palit Deb S. Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death and Differentiation. 20: 558-66. PMID 23238568 DOI: 10.1038/cdd.2012.153 |
0.445 |
|
| 2013 |
Vaughan C, Windle B, Deb S. ChIP sequencing to identify p53 targets. Methods in Molecular Biology (Clifton, N.J.). 962: 227-36. PMID 23150451 DOI: 10.1007/978-1-62703-236-0_19 |
0.382 |
|
| 2013 |
Vaughan C, Deb SP, Deb S. Generation of p53 knock-down cell lines. Methods in Molecular Biology (Clifton, N.J.). 962: 193-9. PMID 23150448 DOI: 10.1007/978-1-62703-236-0_16 |
0.527 |
|
| 2013 |
Frum RA, Deb S, Deb SP. Use of the DNA fiber spreading technique to detect the effects of mutant p53 on DNA replication. Methods in Molecular Biology (Clifton, N.J.). 962: 147-55. PMID 23150444 DOI: 10.1007/978-1-62703-236-0_12 |
0.329 |
|
| 2013 |
Yeudall WA, Wrighton KH, Deb S. Mutant p53 in cell adhesion and motility. Methods in Molecular Biology (Clifton, N.J.). 962: 135-46. PMID 23150443 DOI: 10.1007/978-1-62703-236-0_11 |
0.633 |
|
| 2013 |
Ramamoorthy M, Vaughan C, Deb S, Deb SP. Measurement of chemosensitivity and growth rate in p53 expressing cells. Methods in Molecular Biology (Clifton, N.J.). 962: 127-33. PMID 23150442 DOI: 10.1007/978-1-62703-236-0_10 |
0.434 |
|
| 2013 |
Deb S, Graves PR. Identification of novel mutant p53 interacting proteins by proteomic analysis. Methods in Molecular Biology (Clifton, N.J.). 962: 85-94. PMID 23150439 DOI: 10.1007/978-1-62703-236-0_7 |
0.372 |
|
| 2013 |
Menon V, Peterson E, Deb S, Povirk L, Farrell N. Abstract 3427: The dinuclear platinum agent, BBR3610-DACH, exhibits a significant anti-proliferative effect: Regulation of G1/S and G2/M cell cycle arrest and apoptosis induction. Cancer Research. 73: 3427-3427. DOI: 10.1158/1538-7445.Am2013-3427 |
0.46 |
|
| 2012 |
Vaughan CA, Singh S, Windle B, Yeudall WA, Frum R, Grossman SR, Deb SP, Deb S. Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. Genes & Cancer. 3: 491-502. PMID 23264849 DOI: 10.1177/1947601912462719 |
0.701 |
|
| 2012 |
Vaughan CA, Frum R, Pearsall I, Singh S, Windle B, Yeudall A, Deb SP, Deb S. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochemical and Biophysical Research Communications. 428: 6-10. PMID 22989750 DOI: 10.1016/J.Bbrc.2012.09.029 |
0.712 |
|
| 2012 |
Vaughan CA, Singh S, Windle B, Sankala HM, Graves PR, Andrew Yeudall W, Deb SP, Deb S. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Archives of Biochemistry and Biophysics. 518: 79-88. PMID 22198284 DOI: 10.1016/J.Abb.2011.12.006 |
0.651 |
|
| 2012 |
Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG, Wang H, Black E, Bulysheva AA, Deb SP, Windle B, Deb S. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis. 33: 442-51. PMID 22114072 DOI: 10.1093/Carcin/Bgr270 |
0.687 |
|
| 2011 |
Vaughan C, Mohanraj L, Singh S, Dumur CI, Ramamoorthy M, Garrett CT, Windle B, Yeudall WA, Deb S, Deb SP. Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells. Genes & Cancer. 2: 943-55. PMID 22701761 DOI: 10.1177/1947601911436008 |
0.585 |
|
| 2011 |
Sankala H, Vaughan C, Wang J, Deb S, Graves PR. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Archives of Biochemistry and Biophysics. 512: 52-60. PMID 21621504 DOI: 10.1016/J.Abb.2011.05.005 |
0.713 |
|
| 2011 |
Graves P, Sankala H, Wang J, Vaughan C, Deb S. Upregulation of the Mitochondrial Transport Protein, Tim50, by Mutant P53 Contributes to Cell Growth and Chemoresistance International Journal of Radiation Oncology*Biology*Physics. 81: S55-S56. DOI: 10.1016/j.ijrobp.2011.06.112 |
0.371 |
|
| 2009 |
Frum R, Ramamoorthy M, Mohanraj L, Deb S, Deb SP. MDM2 controls the timely expression of cyclin A to regulate the cell cycle. Molecular Cancer Research : McR. 7: 1253-67. PMID 19671680 DOI: 10.1158/1541-7786.Mcr-08-0334 |
0.573 |
|
| 2008 |
Scian MJ, Carchman EH, Mohanraj L, Stagliano KE, Anderson MA, Deb D, Crane BM, Kiyono T, Windle B, Deb SP, Deb S. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene. 27: 2583-93. PMID 17982488 DOI: 10.1038/Sj.Onc.1210898 |
0.776 |
|
| 2007 |
Frum R, Busby SA, Ramamoorthy M, Deb S, Shabanowitz J, Hunt DF, Deb SP. HDM2-binding partners: interaction with translation elongation factor EF1alpha. Journal of Proteome Research. 6: 1410-7. PMID 17373842 DOI: 10.1021/Pr060584P |
0.407 |
|
| 2005 |
Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Molecular and Cellular Biology. 25: 10097-110. PMID 16260623 DOI: 10.1128/Mcb.25.22.10097-10110.2005 |
0.672 |
|
| 2005 |
Zhou R, Frum R, Deb S, Deb SP. The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells. Cancer Research. 65: 1839-48. PMID 15753382 DOI: 10.1158/0008-5472.Can-03-3755 |
0.435 |
|
| 2004 |
Scian MJ, Stagliano KER, Ellis MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. Modulation of gene expression by tumor-derived p53 mutants Cancer Research. 64: 7447-7454. PMID 15492269 DOI: 10.1158/0008-5472.Can-04-1568 |
0.711 |
|
| 2004 |
Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, Valerie K, Deb SP, Deb S. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene. 23: 4430-43. PMID 15077194 DOI: 10.1038/Sj.Onc.1207553 |
0.765 |
|
| 2004 |
Frum R, Deb SP. Flow cytometric analysis of MDM2-mediated growth arrest. Methods in Molecular Biology (Clifton, N.J.). 234: 257-67. PMID 12824538 DOI: 10.1385/1-59259-408-5:257 |
0.303 |
|
| 2003 |
Scian MJ, Frum R, Deb SP, Deb S. Transactivation and transrepression studies with p53 Methods in Molecular Biology (Clifton, N.J.). 234: 93-110. PMID 12824527 DOI: 10.1385/1-59259-408-5:93 |
0.587 |
|
| 2003 |
Stagliano KE, Carchman E, Deb S. Real-time polymerase chain reaction quantitation of relative expression of genes modulated by p53 using SYBR Green I. Methods in Molecular Biology (Clifton, N.J.). 234: 73-91. PMID 12824526 DOI: 10.1385/1-59259-408-5:73 |
0.643 |
|
| 2002 |
Deb D, Scian M, Roth KE, Li W, Keiger J, Chakraborti AS, Deb SP, Deb S. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants. Oncogene. 21: 176-89. PMID 11803461 DOI: 10.1038/sj.onc.1205035 |
0.781 |
|
| 2001 |
Brown DR, Deb D, Frum R, Hickes L, Munoz R, Deb S, Deb SP. The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants. International Journal of Oncology. 18: 449-59. PMID 11179471 DOI: 10.3892/Ijo.18.3.449 |
0.762 |
|
| 2001 |
Deb D, Lanyi A, Scian M, Keiger J, Brown DR, Le Roith D, Deb SP, Deb S. Differential modulation of cellular and viral promoters by p73 and p53. International Journal of Oncology. 18: 401-9. PMID 11172610 DOI: 10.3892/Ijo.18.2.401 |
0.761 |
|
| 2000 |
Alarcon-Vargas D, Fuchs SY, Deb S, Ronai Z. p73 transcriptional activity increases upon cooperation between its spliced forms. Oncogene. 19: 831-5. PMID 10698502 DOI: 10.1038/Sj.Onc.1203311 |
0.707 |
|
| 1999 |
Deb D, Chakraborti AS, Lányi A, Troyer DA, Deb S. Disruption of functions of wild-type p53 by hetero-oligomerization. International Journal of Oncology. 15: 413-22. PMID 10427119 |
0.775 |
|
| 1998 |
Lányi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, Deb S. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene. 16: 3169-76. PMID 9671396 DOI: 10.1038/sj.onc.1201857 |
0.763 |
|
| 1998 |
Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. The Embo Journal. 17: 2513-25. PMID 9564034 DOI: 10.1093/Emboj/17.9.2513 |
0.399 |
|
| 1996 |
Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Molecular and Cellular Biology. 16: 6009-19. PMID 8887630 DOI: 10.1128/Mcb.16.11.6009 |
0.636 |
|
| 1995 |
Strauss BE, Shivakumar C, Deb SP, Deb S, Haas M. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochemical and Biophysical Research Communications. 217: 825-831. PMID 8554604 DOI: 10.1006/Bbrc.1995.2846 |
0.609 |
|
| 1995 |
Shivakumar CV, Brown DR, Deb S, Deb SP. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter Molecular and Cellular Biology. 15: 6785-6793. PMID 8524244 DOI: 10.1128/Mcb.15.12.6785 |
0.655 |
|
| 1994 |
Martin DW, Deb S. Cloning and expression of an equine herpesvirus 1 origin-binding protein Journal of Virology. 68: 3674-3681. PMID 8189505 DOI: 10.1128/Jvi.68.6.3674-3681.1994 |
0.364 |
|
| 1993 |
Brown DR, Deb S, Muñoz RM, Subler MA, Deb SP. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Molecular and Cellular Biology. 13: 6849-57. PMID 8413278 DOI: 10.1128/Mcb.13.11.6849 |
0.527 |
|
| 1993 |
Martin DW, Subler MA, Muñoz RM, Brown DR, Deb SP, Deb S. p53 and SV40 T antigen bind to the same region overlapping the conserved domain of the TATA-binding protein. Biochemical and Biophysical Research Communications. 195: 428-34. PMID 8395834 DOI: 10.1006/bbrc.1993.2061 |
0.307 |
|
| 1992 |
Deb S, Jackson CT, Subler MA, Martin DW. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. Journal of Virology. 66: 6164-70. PMID 1356162 DOI: 10.1128/jvi.66.10.6164-6170.1992 |
0.647 |
|
| 1989 |
Tack LC, Wright JH, Deb SP, Tegtmeyer P. The p53 complex from monkey cells modulates the biochemical activities of simian virus 40 large T antigen. Journal of Virology. 63: 1310-7. PMID 2521675 DOI: 10.1128/jvi.63.3.1310-1317.1989 |
0.341 |
|
| Show low-probability matches. |